Source: Annual Congress 2012 - Prognostic indices in respiratory infections
Disease area: Respiratory infections

Abstract

Pleural effusions are common and are associated with many diseases. We investigated the usefulness of procalcitonin (PCT) as a diagnostic marker for the cause of pleural effusion. The study was carried out on 54 patients with pleural effusion divided into groups; transudate (n=6),empyema (n=9),T.B (n=8),parapneumonic effusions (PPE) (n=9) and malignant effusions (n=22). Levels of procalcitonin were measured both in serum & pleural effusions. Pleural fluid procalcitonin was highest in empyema 1.17±0.86 ng/ml, next highest in PPE (0.57±0.56 ng/ml), & lowest in transudative effusions (0.06±0.03 ng/ml). Pleural fluid & serum procalcitonin levels positively correlate in both empyema & PPE. The optimal discrimination of patients with empyema could be performed at a cut-off point of pleural fluid procalcitonin 0.09 ng/ml with area under the curve (AUC) of 0.93 (sensitivity 80%,specificity 95%) and at a serum procalcitonin 0.08 ng/ml with AUC of 0.74 (sensitivity 80%,specificity 60%). However, the optimal discrimination of PPE could be performed at a cut-off point of pleural fluid procalcitonin 0.065 ng/ml (sensitivity 78%, specificity 53%) and at a serum procalcitonin 0.054 ng/ml (sensitivity 89%,specificity 33%). The optimal discrimination of patients with (empyema & PPE) could be performed at a cut-off point of pleural fluid procalcitonin 0.075 ng/ml (sensitivity 83%,specificity 58%) and at a serum procalcitonin 0.07 ng/ml (sensitivity 83%,specificity 47%). In conclusion: Pleural fluid PCT is a good and early marker of infection in the pleural space and correlates with the serum PCT in patients with PPE or empyema. Pleural PCT had better diagnostic accuracy than the serum PCT in cases of PPE & empyema.

Rating:

Share or cite this content

Citations should be made in the following way:
M. Yousif, R. El-Helbawy, A. Darwish, H. Fathy, N. El-Helbawy (Shebin El-Kom, Egypt). Usefulness of procalcitonin as a diagnostic marker of pleural effusion. Eur Respir J 2012; 40: Suppl. 56, 2521

Member's Comments

No comment yet.

Related content which might interest you: Utility of pleural fluid for predictive marker testing in malignant pleural effusion Source: Virtual Congress 2020 – Malignant pleural effusion in 2020: understanding the biology and clinical implications Year: 2020 Usefulness of pleural fluid C-reactive protein in differentiation of pleural effusions Source: Annual Congress 2010 - From rare towards common lung diseases: diagnostic and monitoring challenges Year: 2010 Usefulness of pleural fluid C-reactive protein in differentiation of pleural effusions Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Diagnostic accuracy of pleural fluid NTpro-BNP for pleural effusions of cardiac origin Source: Annual Congress 2012 - Novelties in clinical management of thoracic diseases: from diaphragm to pleura Year: 2012 Diagnostic value of procalcitonin and C-reactive protein in the differentiation among bening and malignant pleural effusion Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 The use of pleural fluid C-reactive protein level, as a diagnostic marker for pleural effusions Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Diagnostic usefulness of tumour markers in pleural effusions Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 The diagnostic value of CA-125 in pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 386s Year: 2001 The diagnostic value of pleural fluid C-reactive protein level in pleural effusions Source: Eur Respir J 2002; 20: Suppl. 38, 356s Year: 2002 Pleural fluid procalcitonin levels in identifying pleural effusions due to infection Source: Annual Congress 2009 - Aetiology and diagnosis of lower respiratory tract infections Year: 2009 Procalcitonin and CRP levels in pleural effusions Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Procalcitonin in pleural fluid: A new tool for the diagnosis of empyema and parapneumonic pleural effusions? Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011 Efficacy of bronchoscopy as diagnostic method in pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 247s Year: 2004 Accuracy of pleural fluid c-reactive protein in differentiating between tuberculous and malignant pleural effusions: a meta-analysis Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Value of non-invasive techniques in pleural effusions Source: ERS Skills Course 2015 Year: 2015 Value of pleural fluid and serum NT-ProBNP levels in differentiation of transudative and exudative pleural effusions Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions Year: 2010 Diagnostic value of C-reactive protein in exudative pleural effusions Source: International Congress 2019 – Clinical problems Year: 2019 The diagnostic usefulness of MAGE expression in the diagnosis of exudative pleural effusion Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004 The diagnostic role of pleural fluid and serum Pentraxin-3 levels in the determination of the etiology of pleural effusion Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 Rapid evaluation of exudative pleural effusion using C-reactive protein Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009